

Table A3.1. Evaluation of the cost-effectiveness frontier of screening and decolonisation strategies in an intensive care unit setting, assuming universal pre-emptive decolonisation is excluded. Numbers refer to strategy numbers, where: 1 = baseline 'do nothing'; 5 = universal chromogenic agar screening and decolonisation of MRSA positives (with mupirocin); 6 = universal polymerase chain reaction screening and decolonisation of MRSA positives (with mupirocin). ICER = incremental cost-effectiveness ratio. QALY = quality adjusted life year.

Move between strategies	Cost per admission	QALY per admission	Change in costs, ΔC (compared to previous strategy)	Change in effects, ΔE (compared to previous strategy)	Difference in Costs / Difference in Effects (ICER, cost/QALY)	Option evaluation
Stay at strategy 1	£12,667	9.1623	n/a	n/a	n/a	
Or move:						
to 5	£12,639	9.1741	-£28.44	0.011751	-£2,420	Under threshold
to 6	£12,659	9.1779	£20.25	0.00383	£5,290	Under threshold